Moleculin Biotech said new preclinical studies show its lead drug candidate Annamycin significantly reduced tumor growth across three liver-cancer models—hepatocellular carcinoma, colorectal liver metastases and pancreatic ductal adenocarcinoma liver metastases—while avoiding the heart-toxicity that limits current anthracyclines such as doxorubicin. The liposomal formulation achieved higher concentrations in the liver, spleen, lungs and pancreas than doxorubicin, the company reported at the Shelby-Lavine Pancreatic Cancer Symposium. Earlier clinical testing found no evidence of cardiotoxicity in 32 of 42 patients who received doses above the U.S. Food and Drug Administration’s lifetime anthracycline limit. Annamycin is already in a Phase 3 trial, in combination with cytarabine, for relapsed or refractory acute myeloid leukemia. Moleculin expects initial readouts from that program in the second half of 2025 and is supporting additional investigator-initiated studies aimed at expanding the drug’s use against other hard-to-treat tumors.